AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
fallback

CCQ-L 2.5mg Tablet

Prescription Icon
Prescription Required

Marketer

TTK Healthcare Ltd

Salt Composition

Letrozole (2.5mg)

Overview CCQ-L 2.5mg Tablet

Post-menopausal women with breast cancer may find relief with CCQ-L 2.5mg tablets. This medication can be administered independently or alongside other therapies like surgery or radiotherapy. For patients with advanced breast cancer, it can help inhibit metastasis. CCQ-L 2.5mg tablets can be ingested with or without food, always following the physician's prescribed dosage and duration for optimal results. Dosage frequency varies depending on the treatment goal, determined by your doctor to manage your symptoms effectively. Continuous use as directed is crucial. Common side effects include increased perspiration, weariness, hot flushes, and elevated cholesterol. Report any concerning or persistent side effects to your physician; management strategies may be available. Prior to commencing treatment, inform your doctor of any pre-existing liver or kidney conditions, or a history of osteoporosis. Complete disclosure of all current medications is essential, as interactions may affect CCQ-L's efficacy. Disclose pregnancy or breastfeeding status to your physician. Pre-treatment and ongoing blood tests to monitor vitamin D levels and bone density may be conducted.

Uses of CCQ-L 2.5mg Tablet

Managing breast cancer

Major Benefits of CCQ-L 2.5mg Tablet:

Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. Ingest the 2.5mg CCQ-L tablet whole; avoid chewing, crushing, or breaking it. Consumption with or without food is acceptable, although consistent timing is recommended.

Common Side effects of CCQ-L 2.5mg Tablet:

  • Dizziness
  • Fatigue
  • Weakness
  • Bone pain
  • Back pain
  • Night sweats
  • Joint pain
  • Nausea
  • Osteoporosis
  • Joint inflammation
  • Weight gain
  • Hot flushes
  • Edema (swelling)
  • Flushing (sense of warmth in the face, ears, neck and trunk)
  • Diaphoresis
  • Bone fracture
  • Hypercholesterolemia (high cholesterol)
  • Cough
  • Shortness of breath

How to use CCQ-L 2.5mg Tablet:

Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. Swallow the 2.5mg CCQ-L tablet whole; do not damage it by chewing, crushing, or breaking. While you can consume it with or without food, consistent timing is recommended.

How CCQ-L 2.5mg Tablet works:

Estrogen production is reduced by the aromatase inhibitor CCQ-L 2.5mg Tablet. This lowered estrogen level can inhibit or halt the progression of certain estrogen-dependent breast cancers.

SAFETY ADVICE

AlcoholAlcoholSAFE

Ingesting alcohol alongside a 2.5mg CCQ-L tablet presents no adverse reactions.

PregnancyPregnancyUNSAFE

The use of CCQ-L 2.5mg tablets is strongly contraindicated during pregnancy. Pregnant women should consult their physician; research in both animal and human studies has revealed substantial adverse effects on fetal development.

Breast feedingBreast feedingUNSAFE

Administration of CCQ-L 2.5mg tablets is contraindicated while breastfeeding due to potential infant toxicity. Studies indicate a risk of harmful effects to the nursing infant.

DrivingDrivingUNSAFE

Taking a 2.5mg CCQ-L tablet might reduce alertness, impair vision, and cause drowsiness or dizziness. Driving should be avoided if these effects are experienced.

KidneyKidneySAFE IF PRESCRIBED

The 2.5mg CCQ-L tablet is considered safe for patients with kidney impairment; dosage modification is not typically necessary. Nevertheless, data regarding its use in individuals with terminal kidney failure is scarce. Physician consultation is advised.

LiverLiverCAUTION

Patients with hepatic impairment should exercise caution when using CCQ-L 2.5mg tablets, as dosage modification may be necessary. Physician consultation is advised.

What if you forget to take CCQ-L 2.5mg Tablet :

Should you forget a CCQ-L 2.5mg Tablet dose, administer it promptly. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.

Facts to Know About CCQ-L 2.5mg Tablet

LabelValue
Chemical Type Diphenylmethane-based compound
Developing Habits No.
Type of Therapy Cancer Medications

FAQs on CCQ-L 2.5mg Tablet

CCQ-L 2.5mg tablets are aromatase inhibitors used to treat breast cancer in postmenopausal women.
CCQ-L 2.5mg tablets are anti-estrogens. They work by inhibiting aromatase, an enzyme that produces estrogen. By lowering estrogen levels, they can help prevent the growth of estrogen-dependent breast cancers.
For advanced breast cancer or cancer that has spread, continue taking CCQ-L 2.5mg Tablet until tumor progression. Following tamoxifen or surgery, take CCQ-L 2.5mg Tablet for five years or until recurrence, whichever occurs first. Alternatively, a sequential treatment of two years of CCQ-L 2.5mg Tablet followed by three years of tamoxifen may be used.
While irbesartan and CCQ-L 2.5mg Tablet can be taken together, monitor your blood pressure closely as CCQ-L 2.5mg Tablet may raise it. Consult your doctor if blood pressure management becomes difficult.
While rare, CCQ-L 2.5mg Tablets may be associated with cataracts. Seek immediate medical attention if you develop blurred vision or eye irritation.
Experiencing hot flushes may indicate a common side effect of CCQ-L 2.5mg Tablet, often caused by reduced estrogen. These usually lessen as your body adapts to the medication. However, they might persist throughout treatment, subsiding within months of completion. Consult your doctor if hot flushes are significantly disruptive.
While rare, serious side effects of CCQ-L 2.5mg Tablet can include stroke, angina, heart attack, blood clots, cataracts, osteoporosis, and severe skin reactions.
Taking CCQ-L 2.5mg tablets can lead to bone thinning (osteoporosis) from reduced estrogen. Your doctor may monitor your bone density before, during, and after treatment to check for this.
The Ministry of Health and Family Welfare restricts the use of CCQ-L 2.5mg Tablets to ovulation induction in women with anovulatory infertility.
CCQ-L 2.5mg Tablet
158